MedTrace Logo

A Study of NHL907 in Healthy Adult Participants

NCT07580924 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2026-05-12

No results posted yet for this study

Summary

The goal of this study is to evaluate the safety, tolerability and pharmacokinetics of NHL907 when administered as multiple oral doses in healthy adult participants.

Conditions

  • Healthy Adult Participants

Interventions

DRUG

NHL907

Investigational product NHL907

DRUG

Placebo

NHL907 matching placebo

Sponsors & Collaborators

  • NeuHyll Therapeutics Inc

    collaborator INDUSTRY

  • NeuHyll AUS Pty Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2027-02-28
Completion
2027-04-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07580924 on ClinicalTrials.gov